

28. (new) The process of claim 26, wherein said composition is in the form of a tablet, a powder or a capsule.

29. (new) A composition comprising

(-) 3-[4-[2-phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid or a pharmaceutically acceptable salt thereof, and pharmaceutically acceptable excipients with water content below about 1% and an antioxidant.

30. (new) The composition of claim 29 in the form of a tablet, a powder or a capsule.

31. (new) The composition of claim 29 comprising, expressed in parts by weight per 100 parts of (-) 3-[4-[2-phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid, or of one of its pharmaceutically acceptable salts, and between 1 and 100 parts by weight of an antioxidant and a pharmaceutically acceptable excipients selected from the group consisting of:

between 100 and 400,000 parts by weight of anhydrous lactose,

between 100 and 400,000 parts by weight of lactose monohydrate

between 100 and 400,000 parts by weight of dibasic calcium phosphate

between 50 and 500 parts by weight of pregelatinized starch,

between 1000 and 10,000 parts by weight of microcrystalline cellulose,

between 10 and 500 parts by weight of croscopovidone,

between 10 and 500 parts by weight of silicon dioxide,

between 10 and 500 parts by weight of hydrogenated vegetable oil,

between 10 and 500 parts by weight of magnesium stearate,

between 10 and 500 parts by weight of hydroxypropyl methylcellulose,

between 10 and 500 parts by weight of hydroxypropyl cellulose,

between 1000 and 10,000 parts by weight of mannitol,

between 10 and 500 parts by weight of stearic acid, and
between 10 and 500 parts by weight of titanium dioxide.

32. (new) The composition of claim 31, wherein the pharmaceutically acceptable excipients are selected from the group consisting of:

between 100 and 400,000 parts by weight of anhydrous lactose,
between 100 and 400,000 parts by weight of lactose monohydrate
between 100 and 400,000 parts by weight of dibasic calcium phosphate
between 50 and 500 parts by weight of pregelatinized starch,
between 1000 and 10,000 parts by weight of microcrystalline cellulose,
between 10 and 500 parts by weight of crospovidone,
between 10 and 500 parts by weight of silicon dioxide,
between 10 and 500 parts by weight of hydrogenated vegetable oil,
between 10 and 500 parts by weight of magnesium stearate,
between 10 and 500 parts by weight of hydroxypropyl methylcellulose,
between 10 and 500 parts by weight of hydroxypropyl cellulose,
between 1000 and 10,000 parts by weight of mannitol,
between 10 and 500 parts by weight of stearic acid, and
between 10 and 500 parts by weight of titanium dioxide,
expressed in parts by weight per 100 parts of (-) 3-[4-[2-phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid, or of one of its pharmaceutically acceptable salts.

33. (new) The composition of claim 32, wherein the pharmaceutically acceptable excipients are selected from the from the group consisting of:

lactose and/or cellulose microcrystalline, magnesium stearate, and talc.

34. (new) The composition of claim 32, wherein the pharmaceutically acceptable excipients have a water content below about 0.5%.

35. (new) The composition of claim 32, wherein the pharmaceutically acceptable excipients have a water content below about 0.1%.

36. (new) The composition of claim 32, wherein the pharmaceutically acceptable excipients are in a dry form.

37. (new) The composition of claim 32, wherein the antioxidant is selected from the group consisting of α -tocopherol, γ -tocopherol, δ -tocopherol, extracts of natural origin rich in tocopherol, L-ascorbic acid and its sodium or calcium salts, ascorbyl palmitate, propyl gallate (PG), octyl gallate, dodecyl gallate, butylated hydroxy anisole (BHA) or butylated hydroxy toluene (BHT).

38. (new) The composition of claim 32, wherein the antioxidant is α -tocopherol.

39. (new) The composition of claim 32, associated with at least one customary additive selected from among the sweeteners, flavouring agents, colours and lubricants.

40. (new) A process for the preparation of a composition of claim 32 comprising the step of (a) forming a mixture of (-) 3-[4-[2-phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients and an antioxidant.

41. (new) The process of claim 40, further comprising the step of (b) compressing the mixture.

42. (new) The process of claim 40, characterized in that the process is carried out at water vapour pressure below about 40% and oxygen pressure below about 10%.

43. (new) A composition comprising (-) 3-[4-[2-phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable carriers or excipient wherein said (-) 3-[4-[2-phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid is present in no more than 7.075% by weight.

44. (new) A composition comprising:

(-) 3-[4-[2-phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid, arginine 0.353%

| | |
|----------------------------|------|
| Cellulose Microcrystalline | 20% |
| Lactose | 75% |
| Magnesium Stearate | 0.5% |
| Talc | 4.5% |

45. (new) A composition comprising:

(-) 3-[4-[2-phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid, arginine 7.075%

| | |
|----------------------------|-------|
| Cellulose Microcrystalline | 20% |
| Mannitol | 6.95% |
| Magnesium Stearate | 0.5% |
| Talc | 4.5% |

46. (new) A composition comprising:

(-) 3-[4-[2-phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid, arginine 0.18%

| | |
|--------------------|--------|
| Tabletose 80 | 96.12% |
| Avicel PH 102 | 3.00% |
| Cab-Osil M-3 | 0.20% |
| Magnesium Stearate | 0.50% |